000153SZSE

Fengyuan Pharmaceutical Co., Ltd.

丰原药业

000153

Shenzhen Stock Exchange

Follow
30 announcements tracked· Last: May 18, 2026

Key Financials

As of 2026-05-23T00:00:00.000+00:00
Revenue¥835.9M
Net Profit¥37.0M
ROE1.70%
Debt Ratio58.98%
Monetary Funds¥470.5M
Receivables¥1.06bn
Goodwill¥4.7M
Total Shares464.7M

Announcements

30 total

Announcement on Holding the 2025 Annual Performance Presentation

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on the Approval Notice for the Listing Application of Fumaric Acid Vonoprazan Chemical Raw Materials by Wholly-Owned Subsidiary

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on Obtaining Drug Registration Certificate

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on the Reappointment of Audit Institutions for the Year 2026

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Independent Director 2025 Annual Work Report (Zhang Ruiwen)

Convertible BondsShareholding Change DisclosureListed Company Announcements

Independent Director 2025 Annual Work Report (Wu Cisheng)

Convertible BondsShareholding Change DisclosureListed Company Announcements

Fengyuan Pharmaceutical 2025 Internal Control Audit Report

Share PledgeShareholding Change DisclosureListed Company Announcements

Board's Special Explanation on Matters Involved in the Unqualified Opinion Internal Control Audit Report for the Year 2025 with Emphasis on Matters

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Internal Control Self-Evaluation Report

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Management Measures to Prevent Controlling Shareholders and Related Parties from Occupying Company Funds

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Director and Senior Management Compensation Management System

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

General Manager Work Rules

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Temporary Suspension and Exemption Management System for Information Disclosure

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Senior Management Compensation Plan

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Director Compensation Plan

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on Expected Daily Related Transactions for the Year 2026

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on Providing Guarantees for Working Capital Loans of Wholly-Owned Subsidiaries

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Notice of the 2025 Annual Shareholders' Meeting

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Board Resolution Announcement

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on the Provision for Impairment for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Announcement on the Company's Profit Distribution Plan for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

2026 First Quarter Report

Share Repurchase CompletionShareholding Change DisclosurePeriodic Financial Reports

Board's Report on the Performance of the Accounting Firm and the Audit Committee

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Special Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Share Repurchase CompletionShare PledgeShareholding Change Disclosure

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Share Repurchase CompletionShareholding Change DisclosureListed Company Announcements

Board's Special Opinion on the Self-Examination of Independent Directors' Independence

Share Repurchase CompletionConvertible BondsShareholding Change Disclosure

2025 Annual Audit Report

Share PledgeShareholding Change DisclosureListed Company Announcements

2025 Annual Report

Share Repurchase CompletionShareholding Change DisclosureAnnual Report

2025 Annual Report Summary

Share Repurchase CompletionShareholding Change DisclosureAnnual Report

Special Report on the Cancellation of Illegal Guarantees and the Repayment of Non-Operating Fund Occupation by Related Parties of Anhui Fengyuan Pharmaceutical Co., Ltd. for the Year 2025 and Beyond

Share Repurchase PlanShare PledgeShareholding Change Disclosure

Notes & Comments

Sign in to leave a comment or private note.

Loading…